MedInCell Stock Climbs 4% to €27.06, Targeting Resistance at €28.72
The biotech company from Montpellier gains 4% to €27.06 by midday, ranking among the top risers on the SBF 120. The stock is nearing its resistance at €28.72 and maintains over 72% growth over one year. The rebound occurs in a rising Parisian market, with the SBF 120 up 0.68% during the session.
A Rebound Propels MedInCell Among the Top Gainers on the SBF 120
MedInCell ranks among the top risers on the SBF 120 at midday, alongside technology stocks such as Soitec (+8.98%), Exail Technologies (+7.84%), and STMicroelectronics (+5.12%). The stock has moved back above the €27 threshold after two sessions of consolidation. The movement is part of a well-oriented Parisian market context, with the CAC 40 up by 0.7% and the SBF 120 gaining 0.68% during the session. The bullish momentum remains strong over the long term: the stock retains a 72.8% gain over one year and 12.56% over three months, despite a weekly decline of 1.89%. Declared short positions indicate continued caution around the stock. Three funds together hold 2.07% of the capital in a net short position, a limited increase of 0.11 points over thirty days. This progression does not reflect a massive movement of distrust, but it indicates that some institutional investors remain positioned against the stock or are looking to cover exposure. This point should be monitored, though not interpreted in isolation.
The Stock Approaches Its Resistance at €28.72 After Crossing Its Moving Averages
The price is now above its three reference moving averages. The MM20 (€25.59), the MM50 (€23.59), and the MM200 (€24.79) have all been crossed, with a gap of 5.74% above the MM20 and 14.71% above the MM50. The RSI at 54 remains in the neutral zone, without an overbought configuration. The next graphical threshold is at €28.72, about 6% above the current price, a level that had already hindered the stock in May. The financial calendar provides a clear horizon for investors. The next expected publication concerns the annual results for the April 2025 - March 2026 fiscal year, scheduled for June 16, 2026. The 2026 general meeting is then set for September 10, followed by the semi-annual results on December 8. The shareholder structure, communicated in May 2026, shows 35.1% held by insiders and 31.9% by institutional investors, among them SmallCap World Fund (2.3%). The June 16 meeting will be the next major information point for the Montpellier biotech.
